|
|
Article: IMCLONE WON'T CHANGE DEAL; BMS WILL STAY ON - FOR NOW.(Bristol-Myers Squibb Co.'s partnership with ImClone Systems Inc.)(Brief Article)
- Article from:
- BIOWORLD Today
- Article date:
- February 13, 2002
- Author:
CopyrightCOPYRIGHT 2002 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
The high-stakes game continues.
Like the smaller player in a lively pre-Valentine's Day tennis match, ImClone Systems Inc. lobbed the ball back into Bristol-Myers Squibb Co.'s court early Tuesday, responding with a polite "no, thanks" to the pharmaceutical giant's demand to change the terms of their deal regarding FDA-stalled Erbitux (cetuximab) for colorectal cancer.
Bristol-Myers responded later in the day, saying it was "extremely disappointed" but pledging to continue as a partner - for now. No promises were made for later.
New York-based Bristol-Myers said it is "considering our business and legal options with respect to our ...